Table 2.

Number of Patients with Type and Grade of Toxicity for Doxorubicin-Cyclophosphamide Every 2 Weeks Versus Doxorubicin-Cyclophosphamide Plus Figrastim

Adverse Event	Grade for Doxorubicin-Cyclophosphamide Every 2 Weeks (n = 1,323)								Grade for Doxorubicin-Cyclophosphamide Plus Filgrastim (n = 1,280)
	≤ 2		3		4		5		≤ 2		3		4		5
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
Hemoglobin	1,193	90.2	122	9.2	8	0.6	0	0.0	1,211	94.6	66	5.2	3	0.2	0	0.0
Leukocytes	1,064	80.4	108	8.2	151	11.4	0	0.0	1,090	85.2	145	11.3	45	3.5	0	0.0
Neutrophils	979	74.0	111	8.4	233	17.6	0	0.0	980	76.6	196	15.3	104	8.1	0	0.0
Platelets	1,288	97.4	24	1.8	11	0.8	0	0.0	1,241	97.0	33	2.6	6	0.5	0	0.0
General cardiac	1,312	99.2	8	0.6	3	0.2	1	0.1	1,275	99.6	5	0.4	0	0.0	0	0.0
Clinical mucositis	1,296	98.0	27	2.0	0	0.0	0	0.0	1,173	91.6	105	8.2	2	0.2	0	0.0
Dermatologic/skin	1,295	97.9	28	2.1	0	0.0	0	0.0	1,092	85.3	188	14.7	0	0.0	0	0.0
Infection	1,210	91.5	96	7.3	16	1.2	1	0.1	1,222	95.5	50	3.9	6	0.5	2	0.2
Febrile neutropenia	1,242	93.9	65	4.9	16	1.2	1	0.1	1,255	98.0	22	1.7	3	0.2	0	0.0
Flu-like symptoms	1,209	91.4	107	8.1	7	0.5	0	0.0	1,188	92.8	90	7.0	2	0.2	0	0.0
Other or undetermined							2	0.2							1	0.1
All adverse events	702	53.1	329	24.9	288	21.8	5	0.4	556	43.4	587	45.9	134	10.5	3	0.2